🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Meera Patel

University Health Network

ORCID: 0000-0003-4127-3147

Also affiliated with Baylor College of Medicine, Children's Cancer Center

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer

(2023)10.1158/1078-0432.c.6532896
Top 100%
0DataRank
Top 100%0 citations

Archana Thakur, Wei Chen, Abhinav Deol, Meera Patel, Kimberlee Dobson +9 more

Papers

Driven by 6 papers — median percentile 0. Top paper: “Soluble mesothelin-related peptide as a prognosticator in pleural mesothelioma patients receiving checkpoint immunotherapy”.

Soluble mesothelin-related peptide as a prognosticator in pleural mesothelioma patients receiving checkpoint immunotherapy

Journal of Thoracic and Cardiovascular Surgery(2024)10.1016/j.jtcvs.2024.10.005
N/A
0.330DataRank · unranked
6 citations

Hee-Jin Jang, Allen Kuncheria, Sung Wook Kang, Jong Min Choi, Ji Seon Shim +11 more

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Blood(2020)10.1182/blood.2020006965
N/A
0DataRank · unranked
318 citations

Lindsey E. Roeker, Nicole Lamanna, John N. Allan, Lori A. Leslie, John M. Pagel +57 more

Phase II trial of a novel immunotherapy combination of pembrolizumab and HER2 bi-armed activated T cells (BATs) in metastatic castrate resistant prostate cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.97
N/A
0DataRank · unranked
6 citations

Lawrence G. Lum, Abhinav Deol, Archana Thakur, Elisabeth I. Heath, Wei Chen +4 more

Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1601
N/A
0DataRank · unranked
34 citations

Archana Thakur, Wei Chen, Abhinav Deol, Meera Patel, Kimberlee Dobson +9 more

Data from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer

(2023)10.1158/1078-0432.c.6532896
Top 100%
0DataRank
Top 100%0 citations

Archana Thakur, Wei Chen, Abhinav Deol, Meera Patel, Kimberlee Dobson +9 more

Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-4024
N/A
0DataRank · unranked
3 citations

Meera Patel, Daniel Wang, Sung Wook Kang, Jong Min Choi, Claire Lee +16 more